Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02246647 · ClinicalTrials.gov registry record

Biomarkers for Intestinal Permeability in Patients With Constipation

A clinical trial of Constipation and Irritable Bowel Syndrome, sponsored by Mayo Clinic.

Completed
Registry status
39
Enrollment target
1
Study location

NCT02246647 is a study of Constipation and Irritable Bowel Syndrome that has completed, run by Mayo Clinic. The registered enrollment target is 39 participants, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02246647, a study of Constipation and Irritable Bowel Syndrome, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
39 participants
Enrollment target
1
Study location

Study Summary

Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bowel Syndrome (IBS-C).

Interventions

  • PROCEDURE Esophagogastroduodenoscopy
  • PROCEDURE Flexible sigmoidoscopy
  • DIAGNOSTIC_TEST Permeability measurement

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2014-09
Est. Completion 2016-12-08

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT02246647

The ClinicalTrials.gov registry entry for NCT02246647 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (81% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Constipation appearing as the primary indexed condition, and to 3 interventions - of which Esophagogastroduodenoscopy is the first listed.

NCT02246647 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02246647 about?

NCT02246647 is a clinical study titled "Biomarkers for Intestinal Permeability in Patients With Constipation". Our overall objective with this study is firstly to provide a comprehensive assessment of intestinal permeability, mucosal barrier function using existing biomarkers and secondly to explore novel biomarkers for measuring intestinal permeability in patients with constipation predominant Irritable Bow...

What is the current status of trial NCT02246647?

This trial is currently completed. The enrollment target is 39 participants. The study started on 2014-09. Estimated completion is 2016-12-08.

What conditions does trial NCT02246647 study?

This clinical trial studies the following conditions: Constipation, Irritable Bowel Syndrome, Intestinal Diseases.

What interventions are being tested in trial NCT02246647?

The interventions under investigation include: Esophagogastroduodenoscopy (PROCEDURE), Flexible sigmoidoscopy (PROCEDURE), Permeability measurement (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT02246647?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02246647 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Constipation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.